Biotest AG Announces Delisting and Tender Offer

On March 31, 2025, Biotest AG disclosed a delisting agreement with its principal shareholder, Grifols, S.A., which holds significant shares in Biotest. This agreement involves an application to revoke the trading admission of Biotest's ordinary and preferred shares from the Frankfurt Stock Exchange's regulated market. The company aims to cease the inclusion of its shares in over-the-counter markets, where applicable.

In connection with this, Grifols Biotest Holdings GmbH, a fully owned subsidiary of Grifols, plans to present a public delisting acquisition offer. This offer will target the acquisition of all remaining shares of Biotest AG. Each ordinary share is valued at €43.00, and each preference share at €30.00. The company's management and supervisory boards will review the offer comprehensively before issuing a statement.

Upon completion of the delisting process, Biotest shares will no longer be available on any domestic or comparable foreign market.